UK, YORK – Tissue Regenix Group plc (“Tissue Regenix” or “the Group”) (AIM:TRX), the regenerative medical devices company, today announces the appointment of Randeep Singh Grewal as a non-executive director of the Group.
Randeep will provide valuable assistance to the Group’s management team in delivering Tissue Regenix’s strategy to accelerate the development of a range of products based on its patented dCELL® technology.
Randeep has 15 years’ experience working in the institutional investment arena and, until December 2012, was a senior portfolio manager and member of the European equities team at F&C Asset Management. Randeep has also held investment analyst and portfolio management roles at ICAP Equities and Tudor Capital, where he spent 10 years covering and investing in healthcare companies. Randeep has considerable entrepreneurial expertise, having been involved in a number of start-up companies, both personally and as an investor, and qualified in Medicine from the University of Cambridge.
This appointment represents further progression in the composition of the Board, enhancing the diversity and experience with a group of independent non-executive directors with relevant industry experience, to complement the executive management team and help guide the commercialisation of Tissue Regenix’s products. Randeep’s appointment follows the appointment of Dr. Alison Fielding in November, 2012.
John Samuel, Executive Chairman of Tissue Regenix, said:”We are delighted that Randeep is joining the Tissue Regenix Board and he joins us at an exciting time. We are confident that his insight from an investment community perspective, as well as his in-depth knowledge and analysis of the healthcare sector, will play an invaluable role in allowing the Group to progress further in delivering our focused strategy. We firmly believe his appointment will make a significant contribution to Tissue Regenix as we progress towards full commercialisation of our product range.”
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Related articles
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.